Missolapola

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First DualFunctional RNAi Therapeutic for the Treatment of Mixed HyperlipidemiaJanuary 27, 2026- ARO-DIMER-PA is the fi...

Ik sluit mij hier volledig bij aan, Stock81 en Hulskof (je laatste alinea nog even buiten beschouwing gelaten)!...

Mooi!!Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body CompositionJanu...

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)January 5, 2026– REDEMPLO is the ...

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 EventsDecember 23, 2025PASADENA, Calif.--(BUSINESS WIRE)--Dec. 23, 2025-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today...

Na lange tijd, vandaag terug ingestapt hier...

Top!...

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 ConferencesDecember 1, 2025PASADENA, Calif.--(BUSINESS WIRE)--Dec. 1, 2025-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today...

[quote alias=Altviolist id=15936219 date=202511262343]Ik zit nu al (hardnekkig) 5 jaar in dit aandeel, dus ja, het kan hard onderuit gaan. Maar ik zou hier niet zo lang al door dik en dun in zitten ...

Proficiat aan de zittenblijvers!Ik hou ze alvast stevig vast :-)...

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta TherapeuticsNovember 24, 2025PASADENA, Calif.--(BUSINESS WIRE)--Nov. 24, 2025-- Arrowhead Pharmaceuticals, Inc. (NASDAQ:...

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)November 18, 2025- REDEMPLO is the firs...

www.fda.gov/drugs/novel-drug-approval...Plozasiran goedgekeurd door FDA!...

share.google/Kg8SVSawc3Q2IfhBm...

investorshub.advfn.com/Anavex-Life-Sc...Ook interessant om te volgen...

Via ChatGPT:Inderdaad — de foto toont een officieel EMA-document (CHMP-agenda voor november 2025) waarin vermeld staat dat:Blarcamesine – EMEA/H/C/006475Indicatie: treatment of Alzheimer’s dis...

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 ConferencesNovember 4, 2025PASADENA, Calif.--(BUSINESS WIRE)--Nov. 4, 2025-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today...

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with NovartisOctober 21, 2025PASADENA, Calif.--(BUSINESS WIRE)--Oct. 21, 2025-- Arrowhead Pharmaceuticals,...

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed HyperlipidemiaOctober 7, 2025ARO-DIMER-PA is designed...

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other TauopathiesSeptember 10, 2025 - In preclinical s...

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to SanofiAugust 1, 2025- Sanofi to pay $130 million upfront and up to $265 million in po...

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta TherapeuticsJuly 28, 2025PDF Version- Milestone earned upon reaching first enrollment target in a Phase 1/2 study of ARO-DM1...

PB van gisteren:Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta TherapeuticsPASADENA, Calif.--(BUSINESS WIRE)--Jul. 23, 2025-- Arrowhead Pharmaceut...

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial HypercholesterolemiaJuly 8, 2025- Zodasiran targets ANGPLT3, an e...

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiranir.arrowheadpharma.com/news-releases/...

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA NephropathyMarch 10, 2025- ARO-C3 achieved deep and sustained reductions in alte...

Heb het even nagekeken: op 21/9/20 aangekocht op gemiddeld 4,2 USD en op 7/7/21 verkocht op gemiddeld 25,68 USD. En op 3/1/23 terug aangekocht op 9,64 USD. Nu afwachten hoe de rit zal zijn. Het sen...

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - ARO-INHBE targets a known pathway that signals the body to store fat in adipose tissue- ...

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD12...

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity- In preclinical studies, investigational ARO-ALK7 silenced Activin rec...

Ben ook aan het wachten op AFMD :-)Heb naast ARWR en AFMD ook nog AVXL in de biotech portefeuille...

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 26, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT...

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs- Upon closing, Arrowhead will receive $825 m...

Hier een GAK van $8,79.Fingers crossed!...

x.com/bearbull_trader/status/18596281...‘I went through the updated (14th Nov 2024) institutional holders list of Affimed shares $AFMDWe might be in for a big surprise (ho...

Affimed Reports Third Quarter 2024 Financial Results Business UpdateAFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollm...

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for PlozasiranSeptember 10, 2024PALISADE Phase 3 results demonstrate plozasiran reduced triglycerides by 80% from baseline...

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical StudiesAugust 14, 2024PDF Version- Company hosting an obesity/metabolic RD ...

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortIn...

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerEfficacy and safety of AFM24 in combination with atezolizumab,...

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed HyperlipidemiaMay 29, 2024PDF Version- Zodasiran significantly reduced triglycerides and atherogenic trigl...

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed HyperlipidemiaMay 28, 2024PDF Version- Plozasiran significantly lowered triglyceride levels with commensu...

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinica...

quote:de tuinman schreef op 15 mei 2024 17:55:[...]Ik heb sinds kort Discord. Heb je tips voor me?Geen extra tips, Tuinman.Het wijst zichzelf, gewoon lezen en er het jouw...

We zijn alvast in goed gezelschap met onze visie ;-)...

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressTreatment with AFM28 innate cell engager (ICE®), ...

Artal Group S.A. Top Holdings and 13F Report (2024)www.marketbeat.com/13f-filings/artal-...Heel interessante info van Discord.Dit fonds, gesticht door de rijkste Belg Eric Wittouck...

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyThe preliminary results from the phase 2 study investigating AFM24 in c...

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humanswww.anavex.com/post/anavex-life-scien...